Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.
Actively Recruiting
Atrial fibrillation is the most common heart rhythm problem worldwide and increases the risk of heart failure, stroke, and death. Researchers expect its prevalence to rise, especially in people over 65 years old, with about one in three developing atrial fibrillation. Electrocardioversion is a procedure that restores normal heart rhythm but often results in the arrhythmia returning within a short time. This trial aims to study whether inflammation plays a role in this recurrence and if treating it can reduce the return of atrial fibrillation after electrocardioversion. The trial compares two groups one receives a daily oral dose of 0.5 mg Colchicine for three months, taken in the morning without a loading dose, alongside their usual treatments. The other group receives a matched placebo. This is a randomized, triple-blind Phase 3 study evaluating the effect of low-dose Colchicine on preventing atrial fibrillation recurrence after electrocardioversion. Participants will be monitored for recurrence of atrial fibrillation over six months following electrocardioversion. Researchers will assess the number of arrhythmia recurrences at one, three, and six months, the time to any repeat electrocardioversion, use of antiarrhythmic drugs, and hospitalizations. Safety and overall wellbeing will also be followed during this period, with the main outcome focused on arrhythmia recurrence within six months.
Actively Recruiting
Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.
Actively Recruiting
Researchers are evaluating the impact of core muscle training on the occurrence of incisional hernia, chronic postsurgical pain CPSP, and sarcopenia after abdominal surgery. The study addresses the common practice of limiting core muscle activity post-surgery to prevent hernias, despite no evidence supporting this approach. The trial will explore whether physical restriction or specific core muscle exercises before and after surgery influence the incidence of incisional hernias and the development of CPSP and sarcopenia. Participants will be randomly assigned to one of two groups. The control group will receive standard physiotherapy, which includes early mobilization and exercises to prevent complications, while limiting core muscle activity and weight bearing based on pain. The intervention group will perform four specific core muscle exercises daily during hospitalization under physiotherapist supervision and continue at home for two months, alongside standard physiotherapy. Follow-up visits will occur at two, twelve, and twenty-four months post-surgery. During the study, participants will undergo clinical examinations and ultrasound scans to detect incisional hernias, assessments of chronic postsurgical pain and its treatment, and evaluations of muscle mass using CT scans. Researchers will also monitor exercise activity, hospital stay length, readmission and re-operation rates, and the incidence of sarcopenia. The study period includes regular follow-ups for up to two years to track these outcomes and evaluate the effects of postoperative rehabilitation.
Actively Recruiting
Researchers are evaluating the addition of niraparib to anti-PD-L1 antibody maintenance treatment in patients with SLFN11-positive extensive-disease small cell lung cancer ED-SCLC that has not progressed after standard first-line chemo-immunotherapy. This international, multicenter, single-arm phase II trial aims to assess the clinical effectiveness of this combined treatment approach. The treatment involves giving niraparib orally at a dose of 200 mg once daily, which may be increased to 300 mg daily for patients with body weight 77 kg or higher and platelet counts of at least 150 gL, continuing until disease progression. This is combined with ongoing anti-PD-L1 antibody maintenance therapy following initial chemo-immunotherapy. The trial includes a screening phase for SLFN11 expression in tumor tissue and treatment continues as long as patients meet criteria and tolerate therapy. Participants will be closely monitored with tumor assessments following RECIST v1.1 criteria, tracking progression-free survival at 3 months as the primary outcome. Secondary outcomes include longer-term progression-free survival, overall survival, disease control rate, and adverse events according to CTCAE version 5.0. The total observation period extends approximately 25 to 30 months after the first patient enrollment. Safety and treatment adherence are also evaluated throughout this period.
Actively Recruiting
Researchers are evaluating how pharmacist-guided pre-emptive pharmacogenetic testing can influence the selection and dosing of antidepressant medication for patients diagnosed with moderate to severe depression. The study compares this approach with standard antidepressant treatment where medication decisions are made without genetic testing support. This randomized clinical trial aims to assess the effectiveness and tolerability of antidepressants, with 95 patients planned for each treatment group, all hospitalized and closely monitored during their treatment period. The study involves three groups an intervention group receiving antidepressant therapy guided by pharmacogenetic testing and clinical pharmacist recommendations a standard care group where doctors choose antidepressants based on clinical judgment alone and an observational group for patients who do not require medication adjustments after the first hospitalization week. Pharmacogenetic testing includes genotyping and interpretation using the Stratipharm service to personalize antidepressant selection and dosing. Participants remain hospitalized for at least five weeks, allowing thorough monitoring of treatment response. During the study, participants undergo assessments including their response to antidepressant therapy at 28 days, time to response, remission rates, and changes in depression severity via the HAM-D17 scale. Additional measures include patient self-ratings of depression, side effect evaluations, and tracking of any adverse events related to medication. The study continues monitoring participants until they leave the clinic, with follow-up lasting up to three months to capture time until discharge and longer-term outcomes.
Actively Recruiting
Long-Term Clinical Registry of Z-Systems Zirconia Dental Implants Including Z5-BL and Z5-TL Products
Commercially pure titanium is widely used for dental implants due to its long history, affordability, and variety of designs, dominating over 95% of the implant market. However, there is growing interest in more inert and biocompatible materials like ceramic implants, which offer aesthetic advantages and appeal to patients seeking metal-free dental options. Zirconia implants, previously considered brittle, now show comparable fracture strength to titanium, making them a valuable alternative especially for patients with specific aesthetic or sensitivity needs. This research is an observational registry study conducted by Z-Systems AG to collect long-term clinical data on zirconia dental implants, specifically the Z5-BL and Z5-TL implant types. The registry design allows for capturing real-world benefits and risks without the limitations of patient selection. The study focuses on patients who have received or will receive up to five zirconia implants from these product groups. Participants will be followed at implant surgery and during multiple post-loading visits over several years, up to five years after the final prosthesis placement. Researchers will monitor the absence of persistent complaints, peri-implant infection, and implant mobility at 12 months post-loading. Additional outcomes include the frequency of device-related adverse events and patient satisfaction assessed at surgery, 3 months, 6 months, and annually up to 5 years. The study aims to provide valuable long-term data on the safety and performance of zirconia dental implants in routine clinical practice.
Actively Recruiting
Researchers are studying primary and acquired resistance mechanisms to standard treatments targeting BRAF V600E mutations in metastatic colorectal cancer. This observational study focuses on patients receiving combined therapy with BRAF inhibitor encorafenib, anti-EGFR antibody cetuximab, and chemotherapy. Resistance to this combination often develops, limiting treatment options, so the study aims to uncover genetic and non-genetic reasons behind this resistance to help develop better future therapies. Participants will receive standard-of-care treatment with encorafenib, cetuximab, and possibly chemotherapy. Before starting treatment and at the time of disease progression, researchers will collect tumor tissue, blood, and stool samples. These samples will be used to study molecular changes and the microbiome, and to create patient-derived organoids for laboratory testing. Blood samples will be collected regularly during treatment to analyze circulating tumor DNA over time. Throughout the study, participants will be followed longitudinally with sample collections before treatment and at progression, continuing for up to around 24 months. Researchers will measure molecular alterations linked to resistance, compare tissue and liquid biopsy findings, characterize gut microbiome changes, and track tumor DNA dynamics. The studys findings aim to improve understanding of resistance and support personalized treatment approaches for metastatic colorectal cancer.
Actively Recruiting
Researchers are collecting detailed information about people with cerebral palsy CP in Switzerland through the Swiss-CP-Reg, a national patient registry started in 2017. This registry gathers data on diagnosis, symptoms, treatments, and follow-up care for children, adolescents, and adults with CP. The goal is to better understand CPs prevalence, risk factors, clinical profiles, and needs, ultimately aiming to improve treatment and quality of life. The registry involves multiple Swiss clinics and medical practices and invites all people diagnosed with CP who were born, treated, or live in Switzerland to participate. Data collected include medical records, questionnaires for patients and families, and links to routine statistics and medical registries. Follow-up data are gathered regularly at diagnosis, ages 5, 10, 15, and at the transition to adult care around age 18. The registry also supports clinical research and international collaboration to enhance knowledge exchange and therapeutic approaches. Participants provide informed consent and are followed over time with regular updates on their medical status, motor function, comorbidities, treatments, and quality of life. The registry collects comprehensive information such as birth history, diagnosis details, therapies, surgeries, and socio-economic factors. Data collection includes questionnaires on health, education, and social participation. The study continually analyzes and publishes findings to support better care for people with CP in Switzerland.
Actively Recruiting
Researchers are conducting a post-marketing surveillance study to observe the safety and performance of the SMS femoral stem prosthesis. This observational study involves patients with severely painful or disabling hip conditions such as osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, avascular necrosis of the femoral head, and rheumatoid polyarthritis. The study is sponsored by Medacta International SA and aims to monitor long-term outcomes after primary total hip replacement surgeries. Participants will receive the SMS femoral stem implant as part of their routine primary total hip replacement surgery. The study will observe these patients over a 10-year period to evaluate various outcomes including the survivorship of the implant, clinical and radiographic performance, patient satisfaction, quality of life, patterns of bone remodeling, stem migration, and adverse events. Assessments are scheduled at multiple time points such as 6 weeks, 6 months, 1 year, and annually up to 10 years. During the study, participants will be monitored through clinical evaluations, radiographic imaging, and questionnaires to assess satisfaction and quality of life. The study will track the implants performance and any adverse events over the extended follow-up period. This long-term monitoring aims to provide comprehensive data on how well the SMS femoral stem prosthesis functions and its impact on patients hip health and mobility.